Aurobindo Pharma's Q1 FY 2026-27 Quarterly Results

Result Summary

• Aurobindo Pharma Ltd reported a 5.0% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a growth of 18.1%.
• Its expenses for the quarter were up by 2.4% QoQ and 16.1% YoY.
• The net profit increased 12.1% QoQ and increased 25.2% YoY.
• The earnings per share (EPS) of Aurobindo Pharma Ltd stood at 17.86 during Q1 FY 2026-27.

Financial Statments for Q1 FY 2026-27

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Aurobindo Pharma Ltd is a prominent pharmaceutical company based in India. It is renowned for its extensive portfolio of generic pharmaceuticals and active pharmaceutical ingredients. The company operates across several therapeutic areas, including antibiotics, anti-retrovirals, cardiovascular products, and central nervous system products. Aurobindo Pharma has a significant presence in both the domestic and international markets, exporting to over 150 countries. Recent developments or strategic moves of the company are not available in the provided data.

Revenue

During the first quarter of the fiscal year 2027 (Q1FY27), Aurobindo Pharma Ltd reported a total income of ₹9414.58 crores. This represents a 5.0% increase compared to the previous quarter (Q4FY26), where total income was ₹8970.38 crores. When compared to the same quarter in the previous year (Q1FY26), which was ₹7973.44 crores, there is an 18.1% year-over-year (YoY) increase. The growth in revenue indicates a robust performance in the company's sales efforts across its diverse product lines.

Profitability

In Q1FY27, the company recorded a profit before tax (PBT) of ₹1516.63 crores. This marks a 17.3% increase from the previous quarter's PBT of ₹1293.04 crores and a 25.9% increase from the ₹1204.88 crores reported in Q1FY26. The tax expense for the quarter was ₹483.06 crores, which is a 30.6% rise from the previous quarter and a 26.3% increase year-over-year. The profit after tax (PAT) for Q1FY27 stood at ₹1032.03 crores, up 12.1% QoQ from ₹920.84 crores and 25.2% YoY from ₹824.20 crores. Earnings per share (EPS) for the quarter was ₹17.86, reflecting a growth of 12.6% QoQ and 25.8% YoY.

Operating Metrics

The total expenses for Aurobindo Pharma in Q1FY27 were ₹7857.77 crores, marking a 2.4% increase from the previous quarter's expenses of ₹7677.34 crores and a 16.1% increase from ₹6768.56 crores in Q1FY26. The expenses grew at a slower pace than the total income, contributing to improved profitability metrics. The company exhibited strong operational efficiency, as evidenced by the increment in profit margins. The financial data does not include information required to calculate other financial ratios such as the P/E ratio, debt-to-equity ratio, or current ratio.